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The incorporation of exome and genome sequencing into research and clinical practice raises the possibility of providing a range of 
genomic results to relatives in the event of the death of 
the research participant or patient.1 Genomic data can 
be of direct relevance to the medical care of relatives. 
However, some test subjects (e.g., cancer patients) are 
at higher risk of dying before they receive their test 
results and thus may not be able to share useful infor-
mation with family members. We created an Institu-
tional Review Board (IRB)-approved document with 
talking points on the possibility of disclosure of results 
to family members after an individual’s death to discuss 
during the informed consent process for genomic test-
ing with participants in a study of exome sequencing 
in the context of familial colorectal cancer/polyposis. 
There is general agreement that patients having a 
clinical exome or genome sequencing test should have 
the option of receiving clinically important, medically 
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actionable findings that are unrelated to their diagno-
sis in addition to their diagnostic findings.2 Providers 
customarily recommend that patients disclose these 
findings to their relatives who are at risk for sharing the 
same genetic variants; however, disclosure is generally 
left to the discretion of the patient. If the patient elects 
not to share results, then clinicians and researchers 
generally do not overrule this decision. The dissemi-
nation of research results to the family members of 
research participants may also be encouraged. How-
ever, death or loss of capacity of the patient or partici-
pant prior to receiving these results, including results 
that may be generated based on new knowledge at a 
future time, may prevent test subjects from sharing 
results with relatives. A plan for disclosure to an indi-
vidual designated by the patient or participant prior 
to their death can facilitate return of relevant genomic 
information to surviving family members.3 A passive 
approach of researchers and/or clinicians disclosing 
results only to relatives who seek out this information 
has been advocated by some;4 however, others support 
active and direct disclosure,5 and even an ethical “duty 
to warn” if a finding implies a high risk for the devel-
opment of a severe medically actionable disease in a 
relative.6 While there is not a professional consensus 
on this point, it has been proposed that health care 
professionals have, at a minimum, a responsibility to 
encourage patients to share genetic information with 
family members who may also have an inherited risk.7 
Such encouragement of sharing is part of usual care in 
the medical genetics clinical setting. However, in both 
clinical and research settings, disclosure of results 
after a patient or participant’s death has received little 
attention to date.8
This article reports empirical data concerning 
the decisions of adult participants in cancer-related 
genomic medicine research regarding disclosure of 
their exome sequencing results to family members 
after the participant’s death. We present our approach 
to discussing the potential of return of results in the 
event of death, report preliminary trends in partici-




Adult patients being evaluated for hereditary colorec-
tal cancer and/or polyps at either of two Seattle-area 
participating genetic medicine clinics are offered 
enrollment into the University of Washington, New 
Exome Technology in (NEXT) Medicine study. The 
NEXT Medicine study is a National 
Human Genome Research Institute 
(NHGRI) and National Cancer Institute 
(NCI) funded randomized control trial 
that began enrollment in early 2012. The 
project is part of the Clinical Sequenc-
ing Exploratory Research (CSER) con-
sortium,9 which is investigating the 
incorporation of sequencing technology 
into clinical medicine. NEXT Medicine 
participants are randomized to receive 
standard clinical genetic testing or 
exome sequencing in addition to clinical 
genetic testing. Exome sequencing takes 
place in a clinical laboratory with Clini-
cal Laboratory Improvement Amend-
ments (CLIA) certification. The results 
of exome sequencing are entered into the 
electronic health records of participants as portable 
document format (PDF) reports. All enrolled study 
participants are expected to survive for the duration 
of their enrollment in the trial (approximately 12-14 
months) and have indicated interest in receiving 
medically actionable incidental findings in addition to 
diagnostic genetic results. 
B. Consent 
Either a genetic counselor or a research coordina-
tor conducts informed consent conversations with 
patients for enrollment in the trial. In planning the 
study, we realized that a participant might die before 
receiving exome results, precluding their sharing 
of research findings with family members. Thus, we 
sought approval from the University of Washing-
ton IRB to ask about participants’ wishes regarding 
disclosure of genetic information to another person 
in the event of their death, after they consented to 
enrollment in the study. The content of this discus-
sion is based on the points included in a supplemental 
This article reports empirical data concerning 
the decisions of adult participants in cancer-
related genomic medicine research regarding 
disclosure of their exome sequencing results 
to family members after the participant’s 
death. We present our approach to discussing 
the potential of return of results in the 
event of death, report preliminary trends in 
participant choices, and discuss related legal 
and ethical considerations.
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written consent document which describes the proto-
col (Supplemental Figure 1). That consent document 
was developed based on medical power of attorney 
and record release documents identified by an Inter-
net search of the terms “Power of Attorney, Washing-
ton.” The format was loosely based on the University 
of Washington Medical Center authorization form for 
disclosure or release of protected health information. 
The document states, “Genetic results information is 
important for my blood relatives to learn as we share 
similar genetic material.” However, the document 
does not require that the participant’s designee be a 
blood relative or other family member. Authorization 
for disclosure is valid until a date decided by the par-
ticipant or until the end of the NEXT Medicine study. 
Participants are advised that results disclosed may 
include those generated by both clinical and research 
testing, and that the form will be destroyed when all 
study-related genetic results from the NEXT Medi-
cine study have been provided to that participant. The 
designated individual’s name and contact informa-
tion (mailing address, phone number and/or email 
address), as well as their relationship to the research 
participant, are recorded. Participants are advised 
that we would contact their designee using the con-
tact information they provide, and are not obliged to 
share more than one form of contact information. We 
chose to request only a single designee for logistical 
reasons. Participants who decline to authorize return 
of genetic results to another individual in the event of 
their death are still eligible to participate in the trial. 
Results
To date, 78 participants (33 female and 45 male) 
enrolled in the study have been asked about their 
preference for disclosure of genetic information in 
the event of their death. Forty of these 78 participants 
(51%) were then randomized to exome sequencing 
and 38 (49%) to usual care. The mean age of these 
78 participants was 52 years old (range 19-80 years) 
at the time of enrollment, the majority self-reported 
their ethnicity as Caucasian (80%). The remaining 
participants self-reported their ethnicity as Asian 
(9%), Pacific Islander (1%), or mixed (10%). Eighty-
six percent had a post-high-school education, and 
most had a spouse (including partners; 70.5%). All 
participants had a clinical colorectal cancer genetic 
test ordered due to a personal and/or family history of 
colorectal cancer and/or polyps. Current clinical test-
ing for study participants typically includes ordering 
either colorectal tumor tissue testing to inform tar-
geted gene sequencing or one of several gene sequenc-
ing panels that test for pathogenic variants in genes 
associated with a risk for colorectal cancer and/or 
polyps. Of these 78 participants, 28 had a diagnosis 
of colorectal cancer with or without colon polyps, 42 
had colon polyps and not colorectal cancer, and 8 had 
a suggestive family history without a personal history 
of colorectal cancer or polyps. 
A. Participant Choices
Of these 78 participants, 72 (92%) chose to desig-
nate an individual to receive their genomic results 
Figure 1
Participant Decisions on Return of Genetic Information after Participant Death
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in the case of their death (Figure 1). The decisions of 
male and female participants are presented in Table 
1. While many of the participants made their deci-
sion without noticeable hesitation, a few participants 
deliberated about whether to make a designation and 
whom to designate. In the latter scenario, some partic-
ipants indicated they were considering whether they 
should designate an individual who would be at risk 
to share their genetic findings, as well as whether the 
designated individual would likely disseminate results 
to relevant family members who are also at risk. 
Of those selecting a designee, 47/72 (65%) opted 
for results to be returned to a spouse and 25 (35%) 
designated a blood relative. No one designated anyone 
outside of their family. Family history information was 
available for 39 of the 43 participants who designated 
their spouse. Of these 43 participants, 24 had children 
aged 25 years or less, 6 had no children, and 13 had at 
least one child over the age of 25 years. Of the 25 par-
ticipants designating a blood relative, 3 had children 
aged 25 years or less, 13 had no children, and 9 had 
at least one child over the age of 25 years. The data 
suggest that participants with young children prefer-
entially choose their spouse (Fisher’s exact p-value = 
0.00025). The ages of the children of participants who 
designated a spouse or a blood relative are presented 
in Figure 2.
B. Participants Who Selected a Blood Relative
Of the 25 participants who designated a blood relative, 
9 were currently married or living with a partner, 8 
were never married, and 8 were divorced or widowed. 
More of those blood relatives designated were female 
than is predicted by chance (20/25 or 80% two-tailed 
binomial test p=0.002); 2 designated their mother, 
0 their father, 10 their sister, 2 their brother, 6 their 
daughter, 3 their son, 1 their aunt, and 1 their grand-
mother. All 9 participants (6 female, 3 male) who were 
married or living with a partner but selected relatives 
and not their spouse, selected female relatives. Two of 
Table 1






Return to male 
biological relative
N (%)








Female        17 (52%)  2 (6%) 9 (27%) 5 (15%)  33
Male 30 (67%) 3 (7%) 11 (24%) 1 (2%) 45
Total 47 (60%)  5 (6%) 20 (16%) 6 (8%) 78
Figure 2
Percent of Participants Who Chose a Spouse or Chose a Biological Relative, Comparing Participants 
without Children, with Children <25 Years Old, and with Children >25 Years Old
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the 5 participants who designated male relatives also 
had a female first-degree relative. One of the 3 partici-
pants who designated a son also had a daughter, and 
1 of the 2 participants who designated a brother also 
had a sister. 
C. Participants Who Declined
Of the 6 participants who declined to authorize return 
of results to a specific individual, 1 had no known bio-
logical relatives (as the person was an adoptee) and 1 
had no relationship with living biological family mem-
bers. Neither of these participants had a spouse. The 
remaining 4 participants (5%) had a relationship with 
biological relatives but chose not to have the results 
shared. Two of these participants had a spouse. One 
participant did not feel comfortable making the deci-
sion to share unknown results and wanted to make 
decisions about sharing results after seeing them. 
Another participant felt that his results were private 
information and did not want to burden another indi-
vidual with them. Two participants cited not having 
biological children as their rationale for declining, 
and one of these participants did not want results dis-
closed to her siblings. 
Discussion 
Genetic information differs from other health infor-
mation by providing specific risk information that 
may indicate the need for genetic testing or clinical 
evaluation of biological relatives. While an individual’s 
diagnosis of hypertension, for example, might indicate 
the need for blood pressure screening in a relative, 
genetic test results in an affected family member pro-
vide more specific indication of risk and are essential 
to determine the most cost-effective and informative 
testing strategy in an unaffected relative. In particular, 
a negative result in an unaffected family member can-
not be conclusively interpreted unless that individual 
has been tested for a known pathogenic variant found 
in an affected relative. If an unaffected relative tests 
negative for a known familial pathogenic variant, he 
or she would have the general population risk for the 
disease, rather than the higher risk associated with 
the familial variant. Without knowledge of the genetic 
basis for disease in the affected relative, it would be 
impossible to determine whether an unaffected rela-
tive with a negative test result would be at increased 
risk. Additionally, knowledge of a specific pathogenic 
variant in an affected individual allows direct testing 
for that particular variant in the family, which is faster 
and much less costly than sequencing one or more 
related genes. 
In the context of participants in a cancer genetics 
study, who are also patients having a clinical genetic 
test or that clinical test plus research exome sequenc-
ing, we found that the vast majority of participants 
with a spouse or who had contact with biological rela-
tives (72/76, 95%) chose to designate an individual to 
receive results in the case of their death prior to receiv-
ing the results. The decisions made by female and 
male participants were almost identical. While thus 
far only 4 (5%) participants with a spouse and/or in 
touch with biological relatives declined to designate 
a recipient, it is important to note that this is a choice 
some participants made. In a larger population, 5% 
would constitute a significant number of individuals. 
Most participants choosing a designee selected their 
spouse (65%) and only 8/55 participants (14.5%) with 
a spouse selected a biological relative instead; spouses 
were thus preferred over biological relatives by most 
married or partnered participants. This suggests 
that the spouses, while generally sharing no genetic 
relationship, were trusted to share the information 
appropriately with those at risk. This designation is 
different than the recommendation by geneticists to 
discuss results with relatives who are at risk to share 
the same genetic findings. Most participants (86%) 
who selected a spouse had children and generally 
these children were aged 25 or younger; participants 
may have felt that these children were too young to be 
Genetic information differs from other health information by providing 
specific risk information that may indicate the need for genetic testing or 
clinical evaluation of biological relatives. While an individual’s diagnosis 
of hypertension, for example, might indicate the need for blood pressure 
screening in a relative, genetic test results in an affected family member 
provide more specific indication of risk and are essential to determine the 
most cost-effective and informative testing strategy in an unaffected relative. 
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burdened with the designation to receive the genetic 
results directly. Approximately half of those designat-
ing a blood relative did not have children and only 
12% had children less than 25 years old. Thus, partici-
pants with young children were more likely to select 
their spouse, suggesting that they prioritized the care-
ful dissemination of risk information to their children 
when making this decision. Both male and female 
participants disproportionately selected female fam-
ily members when a spouse was not the designee. 
This likely reflects the previously documented role of 
women as more often being the keepers and sharers of 
family medical information,10 including information 
related to genetic disorders11 and specifically familial 
colorectal cancer.12
Limitations of this work include the small sample 
size and that the participants were all adults from a 
specific patient population (having clinical genetic 
testing for hereditary colorectal cancer and/or pol-
yps). The majority of participants was also of Cauca-
sian ancestry and had post-secondary education. 
Two questions surround our choice of a medical 
power of attorney as the vehicle for designating a rep-
resentative to receive genetic test results following a 
research participant’s incapacity or death. The first 
question is whether this level of documentation is 
necessary: do other legal mechanisms already provide 
adequate access to genetic test results by family mem-
bers? The second question is whether this approach 
is effective: will a medical power of attorney, signed 
while the participant is alive, effectuate the partici-
pant’s wishes to share genetic test results with a desig-
nated family member after death? We examined these 
questions under the assumption that the research 
institution is a HIPAA-covered entity, to which the 
HIPAA Privacy Rule applies.
As amended in 2013,13 the HIPAA Privacy Rule 
treats an individual’s health data as protected health 
information (PHI) for a period of 50 years after death, 
and genetic information is expressly recognized as 
being health information.14 The Privacy Rule recog-
nizes that under applicable law (usually, state law), 
more than one person may have been appointed to 
perform various functions on behalf of a deceased 
person or the deceased person’s estate, and not all 
of these appointed roles warrant access to the dece-
dent’s PHI. The Privacy Rule’s section 164.502(g)(4) 
requires HIPAA-covered entities to treat a person as a 
“personal representative” of the deceased person only 
“with respect to PHI relevant to such personal repre-
sentation.”15 After the 2013 amendments, persons who 
qualify as a personal representative “continue to have 
a right to access the decedent’s protected health infor-
mation relevant to such personal representation, and 
have authority to authorize uses and disclosures of the 
decedent’s protected health information that are not 
otherwise permitted or required by the Privacy Rule.”16 
The amendments recognized, however, that:
family members, relatives, and others, many of 
whom may have had access to the health infor-
mation of the deceased individual prior to death, 
have had difficulty obtaining access to such 
information after the death of the individual, 
because many do not qualify as a “personal rep-
resentative” of the decedent under the Privacy 
Rule at § 164.502(g)(4).17
Accordingly, the amendments created a new access 
pathway under section 164.510(b)(5), which permits 
covered entities “to disclose a decedent’s information 
to family members and others who were involved in 
the care or payment for care of the decedent prior to 
death, unless doing so is inconsistent with any prior 
expressed preference of the individual that is known 
to the covered entity.”18
If an individual dies without having designated a 
personal representative with broad powers to access 
all of his or her medical information after death, most 
states’ laws grant broad powers to a default personal 
representative — often, an executor or administrator 
or close relative of the deceased. The default provi-
sions of state law often are adequate to ensure access 
to genetic test results by biologically related family 
members. This is not always the case, however. For 
example, the default personal representative under 
state law might be the surviving spouse, who may be 
estranged from the deceased’s children from a pre-
vious marriage, who are biological relatives of the 
deceased and have a strong interest in the test results. 
In genomic research, with its potential to generate 
medically significant diagnostic results and inciden-
tal findings, it is prudent to give participants — who 
know their family dynamics better than the state does 
— an opportunity to designate who should receive that 
genomic information. Our empirical results support 
the notion that one-size-fits-all default provisions of 
state law may not meet the needs of all research par-
ticipants: while most participants with a spouse chose 
the spouse, 14.5% did not do so. This suggests that 
research participants may value the opportunity to 
tailor plans for return of their results after death. 
A second question concerns our choice of medi-
cal powers of attorney for this purpose. Under gen-
eral principles of agency law, powers of attorney are 
extinguished upon death of the principal (the person 
who granted the power of attorney) unless special 
circumstances apply.19 The Department of Health 
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and Human Services (HHS) does not automatically 
recognize persons who held medical powers of attor-
ney during a deceased person’s lifetime as personal 
representatives for purposes of accessing informa-
tion after death.20 Whether such people have con-
tinued access to data after death would be a ques-
tion of state law. Family members granted a power 
of attorney to receive genomic results thus may or 
may not qualify as a personal representative for pur-
poses of disclosures after death after under section 
164.502(g)(4). Such people can, however, use the 
medical power of attorney to demonstrate that they 
were involved in the participant’s healthcare prior to 
death, thus allowing access under the Privacy Rule’s 
new section 164.510(b)(5) access pathway created in 
2013. We note, however, that access under section 
164.510(b)(5) is subject to certain limitations: First, 
family members only can gain access to data relevant 
to the role they were playing in the deceased person’s 
healthcare while the deceased was alive (e.g., if they 
only were involved with decisions about cancer care, 
their scope of access would be limited to data relevant 
to that). Second, covered entities are permitted, but 
not required, to disclose results to the family mem-
bers. Finally, access may be subject to confidential-
ity restrictions that the participant requested prior 
to death (such as excluding return to a specific family 
member).21 Despite these limitations, this pathway 
has an offsetting advantage: It avoids any interfer-
ence with the power of the personal representative 
empowered, under other applicable law, to access 
all of the decedent’s medical information. HHS has 
emphasized that the new section164.510(b)(5) path-
way of access for family members “would not change 
the authority of a decedent’s personal representa-
tive.”22 Also, the use of medical powers of attorney 
offers a fairly strong way to ensure focused access 
to incidental findings by the participant’s designee, 
without opening up broad access to the whole of the 
decedent’s medical record by the designee. In devis-
ing an approach to eliciting participant preferences 
on return of results after death or loss of capacity, 
investigators should consider federal, state, and rele-
vant case law applicable to their own research sites.23
In difficult situations where a participant has asked 
that genetic results not be disclosed to a family mem-
ber, the Privacy Rule provides an additional pathway 
for communicating medically important informa-
tion to the surviving relatives.24 The HIPAA Privacy 
Rule allows disclosure of health information without 
an individual’s authorization if the disclosure is for 
“treatment” purposes, and this can include treatment 
of a third party, such as a relative. The Privacy Rule 
“does permit a doctor to disclose protected health 
information about a patient to another health care 
provider for the purpose of treating another patient 
(e.g., to assist the other health care provider with 
treating a family member of the doctor’s patient).”25 
This creates a pathway that allows the information to 
be disclosed to the family member’s health care pro-
viders, who can then use it in deciding appropriate 
follow-up care.
Although we collected these data in the context of 
a research study, all participants were clinic patients 
who had a genetic test as part of their clinical care. Our 
long-term goal is to identify the best and most useful 
processes for managing clinical genomic information. 
In a clinical context, a family member who requests 
the deceased patient’s medical results may not realize 
there could be genetic information present that is also 
relevant to their own health. While a provider aware 
of such relevant information could in theory initiate 
the offer of disclosure to family members after the 
death of a patient, in practice there is not a process for 
this within usual medical care. Our study was carried 
out in a HIPAA-covered research institution, and we 
note that options for sharing a decedent’s test results 
with family members may be even more limited in a 
non-HIPAA-covered research setting. In non-HIPAA 
research settings, IRBs may seek to prevent research-
ers from sharing these data, even if they so desire. 
Thus, documenting a research participant’s desire to 
share genetic information is particularly important. 
The discussion with a patient or participant should 
also allow them to identify with whom they prefer the 
information to be shared. The patient or participant 
is best positioned to know which designee is optimal 
to ensure the dissemination of results to at-risk fam-
ily members. Although our data are limited, the varia-
tion in the relative designated by the participant and 
the apparent preference for a female relative suggest 
that the person designated may not always be the indi-
viduals to whom investigators or clinicians might turn 
without participant guidance, the legal next of kin or 
executor. 
Eliciting preferences for return of results in the 
event of a patient or participant’s death during the 
informed consent process for genomic sequencing 
tests can generate ethical concerns, including con-
cern over imposing genetic information on a designee 
who may be a relative at risk of sharing the variant. 
The designee or other persons they share information 
with are thus potentially learning of a personal genetic 
risk, just as they would have if the patient had shared 
the results. While a relative learning of a genetic risk 
has the autonomy to decide whether to pursue clini-
cal follow-up after receiving such information, they 
cannot unlearn the information that they may be at 
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increased risk. This information may be unexpected 
and unwanted.26 Challenges also arise if the designee 
who receives the results refuses to pass on information 
to at-risk family members. 
A separate issue is whether it is ethically permissi-
ble to give research participants the option to prohibit 
researchers from sharing potentially valuable genomic 
findings with their family members after their death. 
We allow this and, at HIPAA-covered institutions, 
individuals have a right to request privacy protections 
that may include restrictions on disclosures to family 
members.27 However, some observers may object to 
this option as it withholds potentially important med-
ical information, while others may uphold individual 
choice based on personal privacy rights. As noted 
above, when HIPAA applies (that is, when research 
is conducted at an institution that is a HIPAA-cov-
ered entity), confidentiality restrictions requested by 
a research participant may be overcome if the infor-
mation is needed for purposes of treating the family 
member.28 However, the responsibility of health care 
providers to reach out to family members who do not 
seek this information is debatable.29 Under our model, 
we would contact the designated relative, rather than 
waiting to be asked by any family member.
Conclusion
Addressing consent for sharing genomic information 
after death, and with whom the research participant 
wants information shared, should be considered part 
of the consent process for a genomic test. The vast 
majority of participants in our study elected to des-
ignate an individual for return, but participant pref-
erences varied, highlighting the importance of ask-
ing this question prior to the initiation of genomic 
sequencing tests. This is especially important in 
projects addressing cancer and other life-limiting 
conditions; allowing participants to express their 
preferences about the future dissemination of their 
genomic information after death is an important 
dimension of respect for autonomy and privacy. Sim-
ilar considerations militate in favor of eliciting these 
preferences from patients in clinical genomic testing. 
Further research with different study populations 
and in a clinical setting will help refine practices for 
addressing this topic with both patients and research 
participants being consented for genomic sequenc-
ing tests. 
Acknowledgments
This work was funded by the National Institutes of Health 
(NIH), including the National Human Genome Research Insti-
tute (NHGRI) and the National Cancer Institute (NCI) Clini-
cal Sequencing Exploratory Research (CSER) Consortium, 
U01HG006507 and U01HG007307 (Jarvik, PI). Additional sup-
port came from NHGRI U01HG006375 (Jarvik, PI) and NHGRI 
P50 HG003374 (Burke, PI). Editorial review of this article was 
supported by NIH/NCI/NHGRI R01CA154517 (Petersen, Koenig, 
Wolf, PIs). All views expressed are those of the authors and do not 
necessarily reflect the views of NIH, NCI, or NHGRI. 
References 
1.  B. Chan et al., “Genomic Inheritances: Disclosing Individual 
Research Results from Whole-Exome Sequencing to Deceased 
Participants’ Relatives,” AJOB 12, no. 10 (2012): 1-8. 
2.  S. M. Wolf, “Return of Individual Research Results and Inci-
dental Findings: Facing the Challenges of Translational Sci-
ence,” Annual Review of Genomics and Human Genetics 14 
(2013): 557-577; R. C. Green et al., “ACMG Recommendations 
for Reporting of Incidental Findings in Clinical Exome and 
Genome Sequencing,” Genetics in Medicine 15, no. 7 (2013): 
565-574; American College of Medical Genetics, ACMG 
Updates Recommendation on “Opt Out” for Genome Sequenc-
ing Return of Results (2014), available at <https://www.acmg.
net/docs/Release_ACMGUpdatesRecommendations_final.
pdf> (last visited January 15, 2015).
3.   Chan, supra note 1; S. M. Fullerton et al., “Beneficence, Clini-
cal Urgency, and the Return of Individual Research Results 
to relatives,” AJOB 12, no. 10 (2012): 9-10; A. L. Bredenoord 
and J. J. van Delden, “Disclosing Individual Genetic Research 
Results to Deceased Participants’ Relatives by Means of a 
Qualified Disclosure Policy,” AJOB 12, no. 10 (2012): 10-12.
4.  Chan, supra note 1. 
5.  Fullerton, supra note 3. 
6.  Y. Bombard et al., “Risks to Relatives in Genomic Research: A 
Duty to Warn?” AJOB 12, no. 10 (2012): 12-14.
7.  K. Offit et al., “The ‘Duty to Warn’ a Patient’s Family Members 
about Hereditary Disease Risks,” JAMA 292, no. 12 (2004): 
1469-1473.
8.  L. E. Forest et al., “Communicating Genetic Information in 
Families – A Review of Guidelines and Position Papers,” Euro-
pean Journal of Human Genetics 15, no. 6 (2007): 612-618. 
9.  CSER: Clinical Sequencing Exploratory Research, available 
at <https://cser-consortium.org/> (last visited April 2, 2015); 
National Human Genome Research Institute (NHGRI), Clini-
cal Sequencing Exploratory Research (CSER), available at 
<http://www.genome.gov/27546194> (last visited August 1, 
2015).
Addressing consent for sharing genomic information after death, and 
with whom the research participant wants information shared, should be 
considered part of the consent process for a genomic test. The vast majority 
of participants in our study elected to designate an individual for return, but 
participant preferences varied, highlighting the importance of asking this 
question prior to the initiation of genomic sequencing tests. 
genomic research results to a participant’s family • fall 2015 485
Amendola, Horike-Pyne, Trinidad, Fullerton, Evans, Burke and Jarvik
10.  D. Dodd-McCue et al., “The Role of Women in the Donation 
Consent Decision: Building on Previous Research,” Progress in 
Transplantation 17, no. 3 (2007): 209-214.
11.  B. Batte et al., “Family Communication in a Population at Risk 
for Hypertrophic Cardiomyopathy,” Journal of Genetic Coun-
seling 24, no. 2 (2014): 336-348; J. Green et al., “Family Com-
munication and Genetic Counseling: The Case of Hereditary 
Breast and Ovarian Cancer,” Journal of Genetic Counseling 6, 
no. 1 (1997): 45-60.
12.  A. E. Palmquist et al., “’The Cancer Bond’: Exploring the 
Formation of Cancer Risk Perception in Families with Lynch 
Syndrome,” Journal of Genetic Counseling 19, no. 5 (2010): 
473-486.
13.  U.S. Department of Health and Human Services, Office for 
Civil Rights, Modifications to the HIPAA Privacy, Security, 
Enforcement, and Breach Notification Rules Under the Health 
Information Technology for Economic and Clinical Health Act 
and the Genetic Information Nondiscrimination Act; Other 
Modifications to the HIPAA Rules, 78 Federal Register 5566-
5702 (2013).
14.  45 C.F.R. § 160.103 (2014).
15.  45 C.F.R. § 164.502(g)(4) (2014); U.S. Department of Health 
and Human Services, supra note 12, at 5614-15.
16.  U.S. Department of Health and Human Services, supra note 
13, at 5616.
17.  Id., at 5614.
18.  Id., at 5615; see also 45 C.F.R. § 164.510(b)(5) (Providing, 
“Uses and disclosures when the individual is deceased. If the 
individual is deceased, a covered entity may disclose to a fam-
ily member, or other persons identified in paragraph (b)(1) of 
this section who were involved in the individual’s care or pay-
ment for health care prior to the individual’s death, protected 
health information of the individual that is relevant to such 
person’s involvement, unless doing so is inconsistent with any 
prior expressed preference of the individual that is known to 
the covered entity.”).
19.  M. T. Brunner, “What constitutes power coupled with interest 
within the rule as to termination of agency,” 28 A.L.R.2d 1243, 
§§ 1, 11 (1953, updated to 2015).
20.  U.S. Department of Health and Human Services, supra note 
12, at 5616.
21.  45 C.F.R. § 164.522; U.S. Department of Health & Human Ser-
vices, Office for Civil Rights, Health Information of Deceased 
Individuals (2013), available at <http://www.hhs.gov/ocr/
privacy/hipaa/understanding/coveredentities/decedents.html> 
(last visited August 1, 2015).
22.  U.S. Department of Health and Human Services, supra note 
13, at 5615.
23.  Bombard et al., supra note 6; Offit et al., supra note 7.
24.  U.S. Department of Health & Human Services, Office for Civil 
Rights, How Can Family Members of a Deceased Individual 
Obtain the Deceased Individual’s Protected Health Informa-
tion that is Relevant to their Own Care? (2013), available at 
<http://www.hhs.gov/ocr/privacy/hipaa/faq/personal_repre-
sentatives_and_minors/222.html> (August 1, 2015).
25.  U.S. Department of Health & Human Services, Office for Civil 
Rights, Under the HIPAA Privacy Rule, May a Health Care 
Provider Disclose Protected Health Information About an 
Individual to Another Provider, When Such Information Is 
Requested for the Treatment of a Family Member of the Indi-
vidual? (2009), available at <http://www.hhs.gov/ocr/privacy/
hipaa/faq/disclosures_to_friends_and_family/512.html> (last 
visited August 1, 2015). 
26.  K. Galvin and M. L. Clayman, “Disclosure/Disruption: Consid-
ering Why Not to Disclose Genetic Information after Death,” 
AJOB 12, no. 10 (2012): 14-16.
27.  45 C.F.R. § 164.522.
28.  U.S. Department of Health & Human Services, supra note 24.
29.  Bredenoord and van Delden, supra note 3.
